{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:05:28Z","timestamp":1792623928901,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11739-021-02749-1","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T06:03:21Z","timestamp":1620281001000},"page":"2231-2241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections"],"prefix":"10.1007","volume":"16","author":[{"given":"Aaron","family":"Matlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Allan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvan","family":"Moussavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-8869","authenticated-orcid":false,"given":"Brit","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Yuan-Tung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"2749_CR1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the united states 2019","author":"CDC","year":"2019","unstructured":"CDC (2019) Antibiotic resistance threats in the united states 2019. US Department of Health and Human Services. https:\/\/doi.org\/10.15620\/cdc:82532"},{"key":"2749_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11908-018-0629-6","volume":"20","author":"L Nguyen","year":"2018","unstructured":"Nguyen L, Garcia J, Gruenberg K, MacDougall C (2018) Multidrug-resistant pseudomonas infections: Hard to treat, but hope on the horizon? Curr Infect Dis Rep 20:23. https:\/\/doi.org\/10.1007\/s11908-018-0629-6","journal-title":"Curr Infect Dis Rep"},{"key":"2749_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ajem.2017.03.010","volume":"35","author":"A Pourmand","year":"2017","unstructured":"Pourmand A, Mazer-Amirshahi M, Jasani G, May L (2017) Emerging trends in antibiotic resistance: Implications for emergency medicine. Am J Emerg Med 35:1172\u20131176. https:\/\/doi.org\/10.1016\/j.ajem.2017.03.010","journal-title":"Am J Emerg Med"},{"key":"2749_CR4","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1128\/AAC.01103-16","volume":"60","author":"P McGann","year":"2016","unstructured":"McGann P, Snesrud E, Maybank R, Corey B, Ong AC et al (2016) Escherichia coli harboring mcr-1 and blactx-m on a novel incf plasmid: First report of mcr-1 in the united states. Antimicrob Agents Chemother 60:4420\u20134421. https:\/\/doi.org\/10.1128\/AAC.01103-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657\u2013686. https:\/\/doi.org\/10.1128\/CMR.18.4.657-686.2005","journal-title":"Clin Microbiol Rev"},{"key":"2749_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4081\/aiua.2018.2.85","volume":"90","author":"G Perletti","year":"2018","unstructured":"Perletti G, Magri V, Cai T, Stamatiou K, Trinchieri A et al (2018) Resistance of uropathogens to antibacterial agents: emerging threats, trends and treatments. Arch Ital Urol Androl 90:85\u201396. https:\/\/doi.org\/10.4081\/aiua.2018.2.85","journal-title":"Arch Ital Urol Androl"},{"key":"2749_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13613-016-0199-4","volume":"6","author":"G Zilahi","year":"2016","unstructured":"Zilahi G, Artigas A, Martin-Loeches I (2016) What\u2019s new in multidrug-resistant pathogens in the icu? Ann Intensive Care 6:96. https:\/\/doi.org\/10.1186\/s13613-016-0199-4","journal-title":"Ann Intensive Care"},{"key":"2749_CR8","doi-asserted-by":"publisher","first-page":"e0186195","DOI":"10.1371\/journal.pone.0186195","volume":"12","author":"TH McConville","year":"2017","unstructured":"McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier S, Uhlemann AC (2017) Carbapenem-resistant enterobacteriaceae colonization (cre) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS ONE 12:e0186195. https:\/\/doi.org\/10.1371\/journal.pone.0186195","journal-title":"PLoS ONE"},{"key":"2749_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"key":"2749_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PDA Tamma","year":"2020","unstructured":"Tamma PDA, Samuel L et al (2020) Infectious diseases society of america antimicrobial resistant treatment guidance\u202f: Gram-negative bacterial infections. A focus on extended-spectrum \u03b2-lactamase producing enterobacterales (esbl-e), carbapenemresistant enterobacterales (cre), and pseudomonas aeruginosa with difficult-to-treat resistance (dtrp. Aeruginosa). Infectious Disease Society of America Practice Guidelines. Clin Infect Dis 72:169","journal-title":"Clin Infect Dis"},{"key":"2749_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA (2005) Extended-spectrum \u03b2-lactamases: a clinical update. Clin Microbiol Rev 18:657\u2013686. https:\/\/doi.org\/10.1128\/CMR.18.4.657-686.2005","journal-title":"Clin Microbiol Rev"},{"key":"2749_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong D, van Duin D (2017) Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs 77:615","journal-title":"Drugs"},{"key":"2749_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40560-020-0429-6","volume":"8","author":"T Sawa","year":"2020","unstructured":"Sawa T, Kooguchi K, Moriyama K (2020) Molecular diversity of extended-spectrum \u03b2-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care 8:13\u201313. https:\/\/doi.org\/10.1186\/s40560-020-0429-6","journal-title":"J Intensive Care"},{"key":"2749_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13054-019-2371-3","volume":"23","author":"C Cilloniz","year":"2019","unstructured":"Cilloniz C, Dominedo C, Torres A (2019) Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care 23:79. https:\/\/doi.org\/10.1186\/s13054-019-2371-3","journal-title":"Crit Care"},{"key":"2749_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.chest.2019.04.093","volume":"156","author":"BJ Webb","year":"2019","unstructured":"Webb BJ, Sorensen J, Mecham I, Buckel W, Ooi L et al (2019) Antibiotic use and outcomes after implementation of the drug resistance in pneumonia score in ed patients with community-onset pneumonia. Chest 156:843\u2013851. https:\/\/doi.org\/10.1016\/j.chest.2019.04.093","journal-title":"Chest"},{"key":"2749_CR16","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1128\/AAC.02728-15","volume":"60","author":"S Dan","year":"2016","unstructured":"Dan S, Shah A, Justo JA, Bookstaver PB, Kohn J et al (2016) Prediction of fluoroquinolone resistance in gram-negative bacteria causing bloodstream infections. Antimicrob Agents Chemother 60:2265\u20132272. https:\/\/doi.org\/10.1128\/AAC.02728-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1017\/ice.2016.292","volume":"38","author":"MR Augustine","year":"2017","unstructured":"Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J et al (2017) Clinical risk score for prediction of extended-spectrum \u03b2-lactamase-producing enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol 38:266\u2013272. https:\/\/doi.org\/10.1017\/ice.2016.292","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2749_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-16","author":"A Shah","year":"2017","unstructured":"Shah A, Justo JA, Bookstaver PB, Kohn J, Albrecht H et al (2017) Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02313-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR19","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin Infect Dis 63:e61\u2013e111. https:\/\/doi.org\/10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"2749_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/cid\/cis942","volume":"56","author":"Y Doi","year":"2013","unstructured":"Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A et al (2013) Community-associated extended-spectrum beta-lactamase-producing escherichia coli infection in the united states. Clin Infect Dis 56:641\u2013648. https:\/\/doi.org\/10.1093\/cid\/cis942","journal-title":"Clin Infect Dis"},{"key":"2749_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.annemergmed.2018.05.006","volume":"72","author":"BW Frazee","year":"2018","unstructured":"Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R et al (2018) Emergency department urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae: many patients have no identifiable risk factor and discordant empiric therapy is common. Ann Emerg Med 72:449\u2013456. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.05.006","journal-title":"Ann Emerg Med"},{"key":"2749_CR22","doi-asserted-by":"publisher","DOI":"10.3201\/eid2209.160148","author":"DA Talan","year":"2016","unstructured":"Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR et al (2016) Fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing escherichia coli infections in patients with pyelonephritis, united states(1). Emerg Infect Dis. https:\/\/doi.org\/10.3201\/eid2209.160148","journal-title":"Emerg Infect Dis"},{"key":"2749_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10096-019-03533-y","volume":"38","author":"S Leone","year":"2019","unstructured":"Leone S, Damiani G, Pezone I, Kelly ME, Cascella M et al (2019) New antimicrobial options for the management of complicated intra-abdominal infections. Eur J Clin Microbiol Infect Dis 38:819\u2013827. https:\/\/doi.org\/10.1007\/s10096-019-03533-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2749_CR24","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1128\/AAC.03071-15","volume":"60","author":"BJ Webb","year":"2016","unstructured":"Webb BJ, Dascomb K, Stenehjem E, Vikram HR, Agrwal N et al (2016) Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother 60:2652\u20132663. https:\/\/doi.org\/10.1128\/AAC.03071-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcrc.2017.10.036","volume":"44","author":"S Ray","year":"2018","unstructured":"Ray S, Anand D, Purwar S, Samanta A, Upadhye KV et al (2018) Association of high mortality with extended-spectrum beta-lactamase (esbl) positive cultures in community acquired infections. J Crit Care 44:255\u2013260. https:\/\/doi.org\/10.1016\/j.jcrc.2017.10.036","journal-title":"J Crit Care"},{"key":"2749_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01169-07","volume":"52","author":"CG Giske","year":"2008","unstructured":"Giske CG, Monnet DL, Cars O, Carmeli Y, R. ReAct-Action on Antibiotic, (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813\u2013821. https:\/\/doi.org\/10.1128\/AAC.01169-07","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR27","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1128\/AAC.00143-10","volume":"54","author":"M Tumbarello","year":"2010","unstructured":"Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M et al (2010) Costs of bloodstream infections caused by escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 54:4085\u20134091. https:\/\/doi.org\/10.1128\/AAC.00143-10","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13054-015-1000-z","volume":"19","author":"J Garnacho-Montero","year":"2015","unstructured":"Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Fernandez-Delgado E, Lopez-Sanchez JM (2015) Adequate antibiotic therapy prior to icu admission in patients with severe sepsis and septic shock reduces hospital mortality. Crit Care 19:302. https:\/\/doi.org\/10.1186\/s13054-015-1000-z","journal-title":"Crit Care"},{"key":"2749_CR29","unstructured":"Zerbaxa [package insert]. 2014, Cubist Pharmaceuticals: Lexington, MA."},{"key":"2749_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (aspect-cuti). Lancet 385:1949\u20131956. https:\/\/doi.org\/10.1016\/S0140-6736(14)62220-0","journal-title":"Lancet"},{"key":"2749_CR31","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I et al (2015) Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (aspect-ciai). Clin Infect Dis 60:1462\u20131471. https:\/\/doi.org\/10.1093\/cid\/civ097","journal-title":"Clin Infect Dis"},{"key":"2749_CR32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1473-3099(19)30523-7","volume":"19","author":"AC Kalil","year":"2019","unstructured":"Kalil AC, Zavascki AP (2019) Can ceftolozane\u2013tazobactam treat nosocomial pneumonia? Lancet Infect Dis 19:1266\u20131267. https:\/\/doi.org\/10.1016\/S1473-3099(19)30523-7","journal-title":"Lancet Infect Dis"},{"key":"2749_CR33","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/AAC.00296-10","volume":"54","author":"B Moya","year":"2010","unstructured":"Moya B, Zamorano L, Juan C, Ge Y, Oliver A (2010) Affinity of the new cephalosporin cxa-101 to penicillin-binding proteins of pseudomonas aeruginosa. Antimicrob Agents Chemother 54:3933\u20133937. https:\/\/doi.org\/10.1128\/AAC.00296-10","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR34","doi-asserted-by":"publisher","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","volume":"5","author":"JC Gallagher","year":"2018","unstructured":"Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK et al (2018) Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis 5:ofy280. https:\/\/doi.org\/10.1093\/ofid\/ofy280","journal-title":"Open Forum Infect Dis"},{"key":"2749_CR35","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","volume":"96","author":"HS Sader","year":"2020","unstructured":"Sader HS, Flamm RK, Carvalhaes CG, Castanheira M (2020) Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in united states medical centers (2017\u20132018). Diagn Microbiol Infect Dis 96:114833. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2749_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s15010-016-0944-5","volume":"45","author":"A Hernandez-Tejedor","year":"2017","unstructured":"Hernandez-Tejedor A, Merino-Vega CD, Martin-Vivas A, Ruiz de Luna-Gonzalez R, Delgado-Iribarren A et al (2017) Successful treatment of multidrug-resistant pseudomonas aeruginosa breakthrough bacteremia with ceftolozane\/tazobactam. Infection 45:115\u2013117. https:\/\/doi.org\/10.1007\/s15010-016-0944-5","journal-title":"Infection"},{"key":"2749_CR37","unstructured":"Avycaz [package insert]. 2019, GlaxoSmithKline Manufacturing: Verona, Italy."},{"key":"2749_CR38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG et al (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380\u20131389. https:\/\/doi.org\/10.1093\/cid\/ciw133","journal-title":"Clin Infect Dis"},{"key":"2749_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: recapture, a phase 3 randomized trial program. Clin Infect Dis 63:754\u2013762. https:\/\/doi.org\/10.1093\/cid\/ciw378","journal-title":"Clin Infect Dis"},{"key":"2749_CR40","doi-asserted-by":"publisher","first-page":"ofz149","DOI":"10.1093\/ofid\/ofz149","volume":"6","author":"A Torres","year":"2019","unstructured":"Torres A, Rank D, Melnick D, Rekeda L, Chen X et al (2019) Randomized trial of ceftazidime-avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (reprove): analyses per us fda-specified end points. Open Forum Infect Dis 6:ofz149. https:\/\/doi.org\/10.1093\/ofid\/ofz149","journal-title":"Open Forum Infect Dis"},{"key":"2749_CR41","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/jac\/dkw239","volume":"71","author":"M Falcone","year":"2016","unstructured":"Falcone M, Paterson D (2016) Spotlight on ceftazidime\/avibactam: a new option for mdr gram-negative infections. J Antimicrob Chemother 71:2713\u20132722. https:\/\/doi.org\/10.1093\/jac\/dkw239","journal-title":"J Antimicrob Chemother"},{"key":"2749_CR42","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1128\/AAC.02969-15","volume":"60","author":"DJ Buehrle","year":"2016","unstructured":"Buehrle DJ, Shields RK, Chen L, Hao B, Press EG et al (2016) Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant pseudomonas aeruginosa isolates. Antimicrob Agents Chemother 60:3227\u20133231. https:\/\/doi.org\/10.1128\/AAC.02969-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-17","author":"M Grupper","year":"2017","unstructured":"Grupper M, Sutherland C, Nicolau DP (2017) Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00875-17","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR44","unstructured":"Vabomere [package insert]. 2020, Melinta Therapeutics, Inc.: Lincolnshire, IL."},{"key":"2749_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the tango i randomized clinical trial. JAMA J Am Med Assoc 319:788\u2013799. https:\/\/doi.org\/10.1001\/jama.2018.0438","journal-title":"JAMA J Am Med Assoc"},{"key":"2749_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01935-19","author":"R Tsivkovski","year":"2020","unstructured":"Tsivkovski R, Lomovskaya O (2020) Biochemical activity of vaborbactam. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01935-19","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR47","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the tango i randomized clinical trial. JAMA 319:788\u2013799. https:\/\/doi.org\/10.1001\/jama.2018.0438","journal-title":"JAMA"},{"key":"2749_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M et al (2018) Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the tango ii randomized clinical trial. Infect Dis Ther 7:439\u2013455. https:\/\/doi.org\/10.1007\/s40121-018-0214-1","journal-title":"Infect Dis Ther"},{"key":"2749_CR49","unstructured":"Zemdri [package insert]. 2018, Achaogen, Inc.: South San Francisco, CA."},{"key":"2749_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/phar.2203","volume":"39","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC (2019) Plazomicin: a next-generation aminoglycoside. Pharmacotherapy 39:77\u201393. https:\/\/doi.org\/10.1002\/phar.2203","journal-title":"Pharmacotherapy"},{"key":"2749_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM et al (2019) Once-daily plazomicin for complicated urinary tract infections. NEngl J Med 380:729\u2013740. https:\/\/doi.org\/10.1056\/NEJMoa1801467","journal-title":"NEngl J Med"},{"key":"2749_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","volume":"380","author":"J McKinnel","year":"2019","unstructured":"McKinnel J, Jubb A, Daikos GL (2019) Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae. NEngl J Med 380:791\u2013793","journal-title":"NEngl J Med"},{"key":"2749_CR53","unstructured":"Xerava [package insert]. 2018, Tetraphase Pharmaceuticals, Inc.: Watertown, MA."},{"key":"2749_CR54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H (2016) Review of eravacycline: a novel fluorocycline antibacterial agent. Drugs 76:567\u2013588","journal-title":"Drugs"},{"key":"2749_CR55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A et al (2017) Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (ignite 1) trial: a randomized clinical trial. JAMA Surg 152:224\u2013232. https:\/\/doi.org\/10.1001\/jamasurg.2016.4237","journal-title":"JAMA Surg"},{"key":"2749_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","volume":"69","author":"JS Solomkin","year":"2019","unstructured":"Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A et al (2019) Ignite4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis 69:921\u2013929. https:\/\/doi.org\/10.1093\/cid\/ciy1029","journal-title":"Clin Infect Dis"},{"key":"2749_CR57","unstructured":"Nuzyra [package insert]. 2018, Paratek Pharmaceuticals, Inc.: Boston, MA."},{"key":"2749_CR58","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1128\/aac","volume":"63","author":"A Kaushik","year":"2019","unstructured":"Kaushik A, Ammerman NC, Martins O, Parrish NM, Nueremberger EL (2019) In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of mycobacterieum abscessus. Antimicrob Agents Chemother 63:e00470-e519. https:\/\/doi.org\/10.1128\/aac","journal-title":"Antimicrob Agents Chemother"},{"key":"2749_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W et al (2019) Omadacycline for community-acquired bacterial pneumonia. NEngl J Med 380:517\u2013527. https:\/\/doi.org\/10.1056\/NEJMoa1800201","journal-title":"NEngl J Med"},{"key":"2749_CR60","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L et al (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (oasis-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19:1080\u20131090. https:\/\/doi.org\/10.1016\/S1473-3099(19)30275-0","journal-title":"Lancet Infect Dis"},{"key":"2749_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S et al (2019) Omadacycline for acute bacterial skin and skin-structure infections. NEngl J Med 380:528\u2013538. https:\/\/doi.org\/10.1056\/NEJMoa1800170","journal-title":"NEngl J Med"},{"key":"2749_CR62","unstructured":"Recarbrio [package insert]. 2019, Merck & Co., Inc.: Whitehouse Station, NJ."},{"key":"2749_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803","author":"I Titov","year":"2020","unstructured":"Titov I, Wunderink RG, Roquilly A, Rodr\u00edguez Gonzalez D, David-Wang A et al (2020) A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (restore-imi 2 study). Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa803","journal-title":"Clin Infect Dis"},{"key":"2749_CR64","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","volume":"70","author":"J Motsch","year":"2020","unstructured":"Motsch J, Murta de Oliveira C, Stus V, Koksal I, Lyulko O et al (2020) Restore-imi 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 70:1799\u20131808. https:\/\/doi.org\/10.1093\/cid\/ciz530","journal-title":"Clin Infect Dis"},{"key":"2749_CR65","unstructured":"Fetroja [package insert]. 2019, Shionogi & Co., Ltd: Osaka, Japan."},{"key":"2749_CR66","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/s1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328. https:\/\/doi.org\/10.1016\/s1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"key":"2749_CR67","unstructured":"Park F (2020) Study of s-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant gram-negative pathogens- full text view, in ClincalTrials.gov. 2020."}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-021-02749-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:05:36Z","timestamp":1744171536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-021-02749-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2749"],"URL":"https:\/\/doi.org\/10.1007\/s11739-021-02749-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No patients were involved in the production of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The views expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, or the Department of Defense, or the U.S. Government.The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, or the Department of Defense, or the U.S. Government of the information, products, or services contained therein.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}